The Authors carried out a retrospective examination of data relating to 241 patients undergoing radical hysterectomy with pelvic lymphadenectomy between 1970 and 1991. The basic aim of the study was to identify and quantify complications correlated to radical hysterectomy using the Wertheim-Meigs method. Surgery was performed in 223 cases due to cervical cancer, in 13 cases due to endometrial cancer, in 3 cases due to vaginal cancer and in 2 due to ovarian cancer with secondary extension to the uterus. Complications were subdivided into intraoperative and postoperative. Intraoperative complications involved the urinary tract in 4.5% and other apparatus (intestinal and nervous lesions, hemorrhage due to vascular damage) in 8.7% of cases. Postoperative complications were classified as follows: 35.2% involving the urinary tract (fistula 20.3% and vesical dysfunction 14.9%) and 8% involving other organs or systems (infections, neuropathy, pelvic lymphocele, pathologies of intestinal canalization, etc.). Lastly, the Authors examined the individual complications of radical hysterectomy, focusing attention in particular on vesicourethral dyskinesia, in the light of the physiopathological mechanisms reported in the literature. The mean rate of complications in the series examined here was substantially comparable to that reported by other Authors.
Download full-text PDF |
Source |
---|
EClinicalMedicine
February 2025
Department of Breast and Gynaecological Surgery, Institut Curie, Paris, France.
Background: Randomized clinical trials (RCTs) are fundamental to evidence-based medicine, but their real-world impact on clinical practice often remains unmonitored. Leveraging large-scale real-world data can enable systematic monitoring of RCT effects. We aimed to develop a reproducible framework using real-world data to assess how major RCTs influence medical practice, using two pivotal surgical RCTs in gynaecologic oncology as an example-the LACC (Laparoscopic Approach to Cervical Cancer) and LION (Lymphadenectomy in Ovarian Neoplasms) trials.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Department of Pharmaceutical Quality Assurance, SVKM Institute of Pharmacy, Dhule, 424001, India.
Cervical cancer remains a significant global health concern, making it essential to investigate new treatment options continuously. This page provides an overview of the latest advancements and best practices in detection and intervention, including Pap smears, colposcopy, biopsy, immunotherapy, targeted therapies, chemotherapy, radiation therapy, and surgery. Surgical techniques such as radical hysterectomy and minimally invasive procedures have advanced to enhance patient outcomes and quality of life.
View Article and Find Full Text PDFGynecol Oncol
January 2025
Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, The Netherlands.
Objective: Several European and American guidelines recommend to perform an additional hysterectomy in patients with cervical adenocarcinoma in situ (AIS), who initially received conservative treatment and who completed childbearing during follow-up. This study aimed to evaluate cost-effectiveness of performing an additional hysterectomy in comparison to expectative management.
Methods: This post-hoc analysis was based on a retrospective cohort of patients diagnosed with AIS, who were conservatively treated by a radical (i.
Obstet Gynecol
February 2025
Jason D. Wright is from the Department of Obstetrics & Gynecology, Columbia University College of Physicians & Surgeons, New York, New York, and is the Editor-in-Chief of Obstetrics & Gynecology.
Eur J Obstet Gynecol Reprod Biol
January 2025
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; National Clinical Research Center for Obstetric & Gynecologic Diseases, China. Electronic address:
Objective: Clear cell borderline ovarian tumor is a rare subtype of borderline ovarian tumor for which the clinicopathological characteristics, management, and prognosis remain unclear. Herein, we describe the clinical features, treatment options, and prognosis of clear cell borderline ovarian tumors.
Study Design: This was a retrospective study of nine patients with pathologically confirmed clear cell borderline ovarian tumors treated at Peking Union Medical College Hospital between 2006 and 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!